Cargando…

Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks: A retrospective observational study

Pegylated interferon alpha (PEG-IFN-α) is a first-line treatment for patients with chronic hepatitis B (CHB), but its efficacy varies from individual to individual. Early discrimination between responder and non-responder patients is important for optimal clinical management. In addition, low therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yafei, Li, Wei, Liu, Zhongping, Ye, Jun, Zou, Guizhou, Zhang, Zhenhua, Li, Jiabin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738969/ https://www.ncbi.nlm.nih.gov/pubmed/31490387 http://dx.doi.org/10.1097/MD.0000000000017022

Ejemplares similares

Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report
por: Liu, Yu, et al.
Publicado: (2022)

Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients
por: Zhou, Pu, et al.
Publicado: (2015)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report
por: Baik, Su Jung, et al.
Publicado: (2016)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

The response of hepatitis B virus genotype to interferon is associated with a mutation in the interferon-stimulated response element
por: Guo, Yanan, et al.
Publicado: (2019)

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study
por: Chon, Young Eun, et al.
Publicado: (2016)

Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients
por: Li, Min-Ran, et al.
Publicado: (2016)

Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B: A Prospective Observational Study
por: Jia, Wei, et al.
Publicado: (2014)

Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody
por: Lai, Ming-Wei, et al.
Publicado: (2016)

Antenatal administration of hepatitis B immunoglobulin and hepatitis B vaccine to prevent mother to child transmission in hepatitis B virus surface antigen positive pregnant women: A systematic review and meta-analysis
por: Chen, Zhe, et al.
Publicado: (2020)

Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection
por: Yang, Wan-Ting, et al.
Publicado: (2016)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Host Genetic Determinants of Hepatitis B Virus Infection
por: Zhang, Zhenhua, et al.
Publicado: (2019)

Expression and significance of urinary microRNA in patients with chronic hepatitis B
por: Shang, Jia-Wei, et al.
Publicado: (2019)

Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy
por: Geng, Yan, et al.
Publicado: (2016)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B
por: Su, Qian, et al.
Publicado: (2018)

Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B
por: Liu, Liang, et al.
Publicado: (2019)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Virological and serological features of acute hepatitis B in adults
por: Du, Xiaofei, et al.
Publicado: (2017)

A simple noninvasive model to predict significant fibrosis in children with chronic hepatitis B
por: Zhang, Kang-Ling, et al.
Publicado: (2021)

Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels
por: Wang, Lingmei, et al.
Publicado: (2020)

Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
por: Weng, Min, et al.
Publicado: (2013)

Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study
por: Liu, Zhenhua, et al.
Publicado: (2023)

Association Between Catalase Gene Polymorphisms and Risk of Chronic Hepatitis B, Hepatitis B Virus-Related Liver Cirrhosis and Hepatocellular Carcinoma in Guangxi Population: A Case–Control Study
por: Liu, Yanqiong, et al.
Publicado: (2015)

Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B
por: Li, Chang, et al.
Publicado: (2021)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

The Plasma S-adenosylmethionine Level is Associated With the Severity of Hepatitis B-Related Liver Disease
por: Li, Ting, et al.
Publicado: (2015)

Pre-S deletions of hepatitis B virus predict recurrence of hepatocellular carcinoma after curative resection
por: Li-Shuai, Qu, et al.
Publicado: (2017)

Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study
por: Zhu, Yun-Feng, et al.
Publicado: (2019)

Effect of tenofovir on renal function in patients with chronic hepatitis B
por: Jung, Woo Jin, et al.
Publicado: (2018)

Association of telomere length in peripheral leukocytes with chronic hepatitis B and hepatocellular carcinoma
por: Ma, Qiang, et al.
Publicado: (2016)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B
por: Wang, Christina, et al.
Publicado: (2016)

Identification of key candidate genes and pathways in hepatitis B virus-associated acute liver failure by bioinformatical analysis
por: Lin, Huapeng, et al.
Publicado: (2018)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area
por: Hu, Jing-Hong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vjkar5bbg2p4eidhkele5ju80s